NCT04906902View on ClinicalTrials.gov

Acalabrutinib in CNSL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Central Nervous System LymphomaRefractory Central Nervous System LymphomaRecurrent Central Nervous System Lymphoma
Interventions
DRUG

Acalabrutinib

Tablet taken by mouth twice daily

Trial Locations (3)

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER